bioRxivMicrobiologyPreprint
The beneficial role of Candida intermedia and Saccharomyces boulardii yeasts on the immune response of mice vaccinated with a SARS-CoV-2 experimental vaccine
R. E. A. Piraine, N. L. Conrad, V. S. Goncalves, J. V. Ramos, F. P. Leite
Abstract
Non-Saccharomyces yeasts emerge as possible new probiotics with a beneficial effect equal to or greater than the reference probiotic yeast, Saccharomyces boulardii. In this work, we evaluated the immunomodulation effect caused by Candida intermedia in mice vaccinated with inactivated SARS-CoV-2. We conducted preliminary tests using murine macrophages (RAW 264.7) stimulated with viable and heat-killed yeast cells, culture supernatant, and DNA, using qPCR to detect the mRNA transcription. Next, mice were supplemented with C. intermedia before each dose of the SARS-CoV-2 vaccine, and then antibody production was measured by ELISA. The probiotic strain S. boulardii CNCM I-745 was used as a control. We also explored the differences in fecal microbiomes between the non-supplemented and supplemented groups. Live cells of C. intermedia increased the transcription of IL-4, IL-13, and STAT3 by macrophages RAW 264.7, while heat-killed cells up-regulated TNF and Bcl6, and the culture supernatant positively impacted TLR2 transcription. Concanavalin, zymosan, and lipopolysaccharide were used to stimulate splenocytes from C. intermedia-supplemented animals, which showed increased transcription of TNF, IFN{gamma}, IL-4, Bcl6, and STAT3. Sera from these animals showed enhanced levels of anti-SARS-CoV-2 IgG, as well as IgG1 and IgM isotypes, and sIgA in fecal samples. The microbiome of the C. intermedia-supplemented group showed a higher abundance of Bacteroides spp. and Clostridium spp., impacting the Bacteroidetes/Firmicutes balance. We concluded that C. intermedia and S. boulardii could stimulate and impact the gene expression of cells important for innate immunity, influence the composition of the gastrointestinal microbiome, and primarily boost the humoral response after vaccination. Statements and Declarations FundingThe present work was carried out with the support of Conselho Nacional de Desenvolvimento Cientifico (CNPq, Brazil), grant number 150538/2021-9.
- organism: mouse
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Secreted Subunit SARS-CoV-2 RBD-CpE Yeast Oral Vaccine Induces an Adaptive Immune Response in BALB/c Mice
John Donnie Ramos, Christopher Bresnahan, … Nicanor Pier Giorgio Austriaco·bioRxiv·Dec 8, 2025
- Intranasal Nanoemulsion Adjuvanted S-2P Vaccine Demonstrates Protection in Hamsters and Induces Systemic, Cell-Mediated and Mucosal Immunity in Mice
S. Ganesan, H. Acosta, … V. Bitko·bioRxiv·Mar 22, 2022
- Probiotic consortia improve anti-viral immunity to SARS-CoV-2 in ferrets
M. Lehtinen, R. Kumar, … C. R. Budinoff·bioRxiv·Jul 23, 2021
- Intestinal helminth infection impairs vaccine-induced T cell responses and protection against SARS-CoV-2
P. Desai, C. E. Karl, … M. S. Diamond·bioRxiv·Jan 14, 2024
- Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2 in Preclinical Animal Models
J.-G. Park, F. S. Oladunni, … M. Munir·bioRxiv·Jan 8, 2021
- Development of a Novel SARS-CoV-2 Immune Complex Vaccine Candidate (CRCx) with Broad Immune Responses: A Preclinical Trial in Animal Model
K. M. El Sayed Zayed, S. S. Abdulaziz, K. O. Abdallah·bioRxiv·May 27, 2022